NCT05074043

Brief Summary

We aimed to describe the frequency; presentations, predictors, in-hospital outcome of mucormycosis patients in the scope of COVID-19. All patients with COVID-19 associated Mucormycosis (CAM) admitted to Assuit University Hospital between March 1, 2021, and July 30, 2021, were included in this study. The patient characteristics, the site of mucormycosis, the comorbidities, the steroids usage, and the outcome were analyzed in people with COVID-19.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
433

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2021

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2021

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 30, 2021

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

October 5, 2021

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 12, 2021

Completed
Last Updated

October 12, 2021

Status Verified

October 1, 2021

Enrollment Period

4 months

First QC Date

October 5, 2021

Last Update Submit

October 5, 2021

Conditions

Mucormycosis

Outcome Measures

Primary Outcomes (1)

  • incidence of covid19 associated mucor

    3 months

Study Arms (2)

covid19

covid 19 proven by clinical, PCR. not associated with mucor

covid19 associated with mucor

covid19 associated with mucor proven by clinical, histopathological

Combination Product: antiviral, surgical

Interventions

antiviral, surgicalCOMBINATION_PRODUCT

surgical debridment

covid19 associated with mucor

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Participants with mucormycosis in a confirmed diagnosis of COVID-19

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Marwa Abdelrady

Asyut, 11711, Egypt

Location

MeSH Terms

Conditions

Mucormycosis

Interventions

Antiviral AgentsSurgical Procedures, Operative

Condition Hierarchy (Ancestors)

ZygomycosisMycosesBacterial Infections and MycosesInfections

Intervention Hierarchy (Ancestors)

Anti-Infective AgentsTherapeutic UsesPharmacologic ActionsChemical Actions and Uses

Study Design

Study Type
observational
Observational Model
CASE CROSSOVER
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
lecturer

Study Record Dates

First Submitted

October 5, 2021

First Posted

October 12, 2021

Study Start

March 1, 2021

Primary Completion

June 30, 2021

Study Completion

July 30, 2021

Last Updated

October 12, 2021

Record last verified: 2021-10

Locations

EG(1)